Our data suggest that the influence of KCNK9 on pacemaker frequency and potentially in vivo activity could be feasible as a therapeutical strategy for attention deficit and hyperactivity disorder (ADHD). This evidence concerns the gene KCNK9 and attention deficit-hyperactivity disorder.